According to the Zhitong Finance App, Mengke Pharmaceutical (688373.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 30.161,000 yuan, an increase of 91.1% over the previous year; a net loss attributable to shareholders of listed companies of 102 million yuan; a net loss of 108 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss; and a basic loss of 0.16 yuan per share.